Adicet Bio (FRA:1IJ) Total Current Liabilities: €15.83 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €7.15
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Total Current Liabilities?

Adicet Bio FRA:1IJ -3.38% 31 Total Current Liabilities is €15.83 Mil as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Adicet Bio's total current liabilities for the quarter that ended in Mar. 2026 was €15.83

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Adicet Bio Total Current Liabilities Related Terms

Adicet Bio Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Total Current Liabilities Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial 14.44 18.60 17.69 18.52 18.39

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.21 14.81 16.14 18.39 15.83
FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Adicet Bio's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.857+2.721
+Other Current Liabilities+Current Deferred Liabilities
=4.809+0
=18.39

Adicet Bio's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.136+2.49
+Other Current Liabilities+Current Deferred Liabilities
=3.202+0
=15.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €15.83 Mil mean?
Adicet Bio (FRA:1IJ) has a Total Current Liabilities of €15.83 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Adicet Bio and its competitors.
Is Adicet Bio's Total Current Liabilities too high?
Adicet Bio's current Total Current Liabilities is €15.83 Mil. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Total Current Liabilities compare to EDSA and GOSS?
Adicet Bio's Total Current Liabilities of €15.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Adicet Bio and its competitors. Adicet Bio's current Total Current Liabilities is €15.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Total Current Liabilities of €15.83 Mil. The current Total Current Liabilities is €15.83 Mil. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Total Current Liabilities is €15.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.15
Price